Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data

Abstract

NGS panel testing allowed MP-guided treatment in only 4.7% (6/127) of patients with advanced breast cancer in a real-world setting. The availability of matched drugs is critical for the realistic implementation of personalized treatment.